EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inhibrx Biosciences's enterprise value is $22.21 Mil.
Inhibrx Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $1,743.58 Mil. Therefore, Inhibrx Biosciences's EV-to-EBITDA for today is 0.01.
The historical rank and industry rank for Inhibrx Biosciences's EV-to-EBITDA or its related term are showing as below:
INBX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.5 Med: -0.01 Max: 0.03
Current: 0.01
During the past 2 years, the highest EV-to-EBITDA of Inhibrx Biosciences was 0.03. The lowest was -1.50. And the median was -0.01.
INBX's EV-to-EBITDA is ranked better than 97.09% of 447
companies
in the Biotechnology industry
Industry Median: 9.29
vs INBX: 0.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Inhibrx Biosciences EV-to-EBITDA Historical Data
The historical data trend for Inhibrx Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibrx Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, Inhibrx Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's EV-to-EBITDA falls into.
Inhibrx Biosciences's current Enterprise Value is $22.21 Mil.
Inhibrx Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,743.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inhibrx Biosciences's PE Ratio (TTM) for today is calculated as:
Inhibrx Biosciences's share price for today is $15.12.
Inhibrx Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $118.674.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Inhibrx Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your